Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
about
A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.Vaccine adjuvants as potential cancer immunotherapeuticsMixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvantsSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewEmulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in miceImmunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicityAn update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Emulsion-based adjuvants for influenza vaccines.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsPhase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Babassu aqueous extract (BAE) as an adjuvant for T helper (Th)1-dependent immune responses in mice of a Th2 immune response-prone strain.Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.Generation of more effective cancer vaccinesCellular and vaccine therapeutic approaches for gliomasProtective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat regionTrial Watch: Peptide-based anticancer vaccines.Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Protective immunity to Japanese encephalitis virus associated with anti-NS1 antibodies in a mouse model.Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primatesVaccines for tuberculosis: novel concepts and recent progress.Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb tApplications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.Improving vaccines by incorporating immunological coadjuvants.Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.Systematic identification of small molecule adjuvants.Physicochemical and functional characterization of vaccine antigens and adjuvants.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.
P2860
Q24816925-3A312988-40BA-4290-BCEB-1D71C4F943E9Q26752522-6F82DFAB-A245-4BF8-9CB1-C3C0C83BC992Q27304735-2592D021-B256-428D-A671-AC56E2888BEEQ28084805-CAFBD3C1-5DB3-4C2A-80AF-C4200746539AQ28749625-87A97830-5B89-42F5-85EC-1B5AC51C7906Q28749845-63FADA89-9190-4C9E-8ED7-8BD28554FCF1Q30352329-7413B09F-146D-4265-B09D-3B266DC13181Q30375985-01EF4A4D-5E5F-439F-BF33-4B0421D4007BQ33350210-A502EAEE-3D63-4D5D-9CE5-A2CEFED36591Q33394245-CA32C36A-DA12-4900-92F7-F45084B451BFQ33665793-2DEC8A1F-E9C2-4063-AB50-D2259AF20E51Q33703139-48CFE848-94E6-4F9C-A7E9-F3781FA246C9Q33721641-B76992B6-C788-489F-8199-FB895A5144B8Q33762869-3BFC87E9-058B-4BA0-AADC-09402910086FQ33806434-EB23F357-17EC-4E27-9026-591D5AD8E4E9Q33946907-C8B2C598-DBEC-4B00-9C77-4CBC4869C13DQ33997622-5E892BC6-3C29-40D5-8C8A-751F42EC85F5Q34169981-58E8A726-1EA4-462E-811A-4E52CE077BCAQ34243550-42F4A2BE-F539-449F-BABB-8FDEE004AAE0Q34350954-887BC298-B91B-4377-BD4F-87E059FB9026Q34483345-B1E2884F-8864-4053-92F0-EFD6B26D7BCCQ34951967-1254DE59-A490-4989-9B92-27238CBE608DQ35557657-5601CDDD-3B4D-47A5-AB5D-F49E83FABECDQ36156558-2CAE4FAC-2412-4DE4-99BC-11C46E3724C0Q36238083-0A62D315-7533-48D1-97A4-D3981E49D674Q36285657-5F48579C-0973-47C7-A6A6-2AEB5278AEF2Q36334550-B2B4D097-1413-45AF-B449-620555DD0B42Q36591050-69F63BB6-32AA-4F7B-BE64-8C7B8ABEB4BDQ36710710-B189761B-D5C2-404E-BEF4-E471D9B566D4Q36766857-3FB487D3-1E26-409B-866B-112ED193233AQ36899084-9EAE603E-DD68-492A-88EA-72B27CC3CD9CQ37098801-3C75C1CE-A61A-43BF-B9C9-A9CD656E40D2Q37355242-5528498F-E3D9-48E6-B55A-CA512CB61E79Q37434385-16C14434-2E19-4CF1-A08A-FFDBE0DDC948Q37523834-13DB60D4-F040-452E-9CD8-B7DE18AFAB35Q37523971-42DB8459-1B79-4D1D-AE6C-BCF9F52A20B4Q38020881-01622C85-2D1A-479B-A508-8E5AAD15D4F8Q38202170-9D5EE218-BAC8-4C7B-B4A0-F4817F44DD28Q38260496-767F0D04-1B1F-4B8D-8736-7888258AFF2CQ38264288-3F0B94D2-2323-4C6E-8053-17614A33CAA3
P2860
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@en
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@nl
type
label
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@en
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@nl
prefLabel
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@en
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@nl
P2093
P2860
P356
P1476
Montanide ISA 720 and 51: a ne ...... adjuvants for human vaccines.
@en
P2093
Jerome Aucouturier
S Ascarateil
P2860
P304
P356
10.1586/14760584.1.1.111
P577
2002-06-01T00:00:00Z